You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Repligen Corporation issued $1.0 billion of 0.25% Convertible Senior Notes due 2031 on November 6, 2026, raising approximately $458.6 million in cash and exchanging approximately $456.8 million principal of 2028 Notes.
Repligen completed the BioLife acquisition for approximately $1.9 billion on October 6, 2026. Nine-month product revenue rose 12.5%, while Repligen recorded a $41.2 million intangible asset impairment charge.
Repligen Corporation announced $1.0 billion of 0.25% Convertible Senior Notes due 2031, comprising $541.4 million exchanged for $456.8 million of 2028 Notes and $458.6 million issued for cash; closing is expected on or about November 6, 2026.
Repligen reported third-quarter revenue of $209 million and raised 2026 revenue guidance to $844 to $852 million. For 2027, it expects reported growth of at least 25% and revenue exceeding US$1 billion.
Repligen reported Q3 revenue of $209.3 million, up 11% as reported and 12.5% organically, completed the BioLife acquisition on October 6, 2026, and raised FY 2026 reported revenue guidance to $844M - $852M, representing 14.5% - 15.5% growth.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGEN
this stock
Repligen Corp
|
$10.73B | +2.4% | +35.1% | — | 11.0% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Repligen Corporation issued $1.0 billion of 0.25% Convertible Senior Notes due 2031 on November 6, 2026, raising approximately $458.6 million in cash and exchanging approximately $456.8 million principal of 2028 Notes.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGEN | -3.3% | -4.4% | +45.7% | -5.2% | +2.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -5.9% | -3.2% | +45.2% | -5.0% | -8.2% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
